Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 17000 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Up 60.0 %
The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The firm’s fifty day simple moving average is C$0.01 and its 200-day simple moving average is C$0.01. The company has a market cap of C$1.06 million, a PE ratio of -0.80 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- What is a Dividend King?
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- High Flyers: 3 Natural Gas Stocks for March 2022
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Upcoming IPO Stock Lockup Period, Explained
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
